Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):2053–2056. doi: 10.1128/aac.41.9.2053

In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

M Manduru 1, L B Mihm 1, R L White 1, L V Friedrich 1, P A Flume 1, J A Bosso 1
PMCID: PMC164067  PMID: 9303416

Abstract

The concentration/MIC (C/MIC) ratio maximizing the bactericidal activity of ceftazidime against 10 Pseudomonas aeruginosa isolates from cystic fibrosis patients was identified. Bactericidal activity was assessed by determining the percent difference in the area under the killing curve at each C/MIC ratio for all of the isolates from that of their growth control. The percent effect at each C/MIC ratio was fitted to a sigmoidal Emax model with maximum bactericidal activity defined as the C/MIC ratio that produced an effect that was 90% of the Emax. Our results suggest that at least some isolates may require higher C/MIC ratios than previously reported for maximal activity.

Full Text

The Full Text of this article is available as a PDF (170.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benko A. S., Cappelletty D. M., Kruse J. A., Rybak M. J. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996 Mar;40(3):691–695. doi: 10.1128/aac.40.3.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodey G. P., Ketchel S. J., Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med. 1979 Oct;67(4):608–616. doi: 10.1016/0002-9343(79)90242-0. [DOI] [PubMed] [Google Scholar]
  3. Bolister N., Basker M., Hodges N., Marriott C. Reduced susceptibility of a mucoid strain of Pseudomonas aeruginosa to lysis by ticarcillin and piperacillin. J Antimicrob Chemother. 1989 Oct;24(4):619–621. doi: 10.1093/jac/24.4.619. [DOI] [PubMed] [Google Scholar]
  4. Bourne D. W. BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Comput Methods Programs Biomed. 1989 Jul;29(3):191–195. doi: 10.1016/0169-2607(89)90129-6. [DOI] [PubMed] [Google Scholar]
  5. Cappelletty D. M., Kang S. L., Palmer S. M., Rybak M. J. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995 Aug;39(8):1797–1801. doi: 10.1128/aac.39.8.1797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Craig W. A., Ebert S. C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992 Dec;36(12):2577–2583. doi: 10.1128/aac.36.12.2577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Daenen S., Erjavec Z., Uges D. R., De Vries-Hospers H. G., De Jonge P., Halie M. R. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis. 1995 Mar;14(3):188–192. doi: 10.1007/BF02310354. [DOI] [PubMed] [Google Scholar]
  8. Daenen S., de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet. 1988 Apr 23;1(8591):937–937. doi: 10.1016/s0140-6736(88)91741-2. [DOI] [PubMed] [Google Scholar]
  9. David T. J., Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989 Jun 24;1(8652):1454–1455. doi: 10.1016/s0140-6736(89)90164-5. [DOI] [PubMed] [Google Scholar]
  10. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gerber A. U., Feller C., Brugger H. P. Time course of the pharmacological response to beta-lactam antibiotics in vitro and in vivo. Eur J Clin Microbiol. 1984 Dec;3(6):592–597. doi: 10.1007/BF02013630. [DOI] [PubMed] [Google Scholar]
  12. Hodges N. A., Gordon C. A. Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate. Antimicrob Agents Chemother. 1991 Nov;35(11):2450–2452. doi: 10.1128/aac.35.11.2450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Holford N. H., Sheiner L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429–453. doi: 10.2165/00003088-198106060-00002. [DOI] [PubMed] [Google Scholar]
  14. Kuzemko J., Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989 Aug 12;2(8659):385–385. doi: 10.1016/s0140-6736(89)90561-8. [DOI] [PubMed] [Google Scholar]
  15. Leggett J. E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb;159(2):281–292. doi: 10.1093/infdis/159.2.281. [DOI] [PubMed] [Google Scholar]
  16. Mouton J. W., Vinks A. A. Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations. J Antimicrob Chemother. 1996 Jul;38(1):5–15. doi: 10.1093/jac/38.1.5. [DOI] [PubMed] [Google Scholar]
  17. Mouton J. W., den Hollander J. G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994 May;38(5):931–936. doi: 10.1128/aac.38.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nicolau D. P., Nightingale C. H., Banevicius M. A., Fu Q., Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996 Jan;40(1):61–64. doi: 10.1128/aac.40.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Roosendaal R., Bakker-Woudenberg I. A., van den Berghe-van Raffe M., Michel M. F. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother. 1986 Sep;30(3):403–408. doi: 10.1128/aac.30.3.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schentag J. J., Smith I. L., Swanson D. J., DeAngelis C., Fracasso J. E., Vari A., Vance J. W. Role for dual individualization with cefmenoxime. Am J Med. 1984 Dec 21;77(6A):43–50. doi: 10.1016/s0002-9343(84)80074-1. [DOI] [PubMed] [Google Scholar]
  21. Shah P. M., Junghanns, Stille W. Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus. Dtsch Med Wochenschr. 1976 Feb 27;101(9):325–328. doi: 10.1055/s-0028-1104083. [DOI] [PubMed] [Google Scholar]
  22. Vinks A. A., Touw D. J., Heijerman H. G., Danhof M., de Leede G. P., Bakker W. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit. 1994 Aug;16(4):341–348. doi: 10.1097/00007691-199408000-00002. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES